 BOSTON and LONDON, Jan. 19, 2021 GLOBE NEWSWIRE -- Orchard Therapeutics Nasdaq: ORTX, a global gene therapy leader, today announced plans to extend the companys commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and GEN, two leading regional specialty pharmaceutical companies with extensive experience in rare genetic disease. GenPharm and GEN will collaborate with Orchard to facilitate access to treatment with Libmeldy in European-based qualified treatment centers for eligible patients living in the Middle East and Turkey. 